{"product_id":"medipal-hd-pestle-analysis","title":"Medipal Holdings PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our concise PESTLE Analysis of Medipal Holdings—highlighting regulatory, economic, and technological forces shaping its healthcare distribution business and growth prospects; ideal for investors and strategists seeking a quick edge. Purchase the full report to access detailed risk assessments, market scenarios, and actionable recommendations you can deploy immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnnual NHI Drug Price Revisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Japanese government’s annual National Health Insurance drug price revisions—which trimmed average listed prices by about 1.6% in 2024 and cumulatively over 10% since 2015—aim to curb rising healthcare spending and directly compress wholesalers’ gross margins.\u003c\/p\u003e\n\u003cp\u003eFor Medipal Holdings, these systematic cuts reduced gross margin pressure in FY2024, where the pharma distribution sector saw median gross margins fall toward low single digits, forcing tighter margin management. \u003c\/p\u003e\n\u003cp\u003eTo mitigate impact, Medipal is boosting operational efficiency—targeting SG\u0026amp;A savings and logistics automation—and shifting toward higher-margin specialty medicines and services, which accounted for an increasing share of revenue in 2023–24. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity-based Integrated Care System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment policy is shifting to a decentralized model favoring home-based care and regional coordination, with Japan's Ministry of Health targeting a 20% increase in community-based care capacity by 2025; Medipal is aligning distribution to support these networks by offering integrated logistics to ~65,000 clinics and pharmacies nationwide, adapting delivery frequency and inventory management to localized demand patterns, impacting working capital and reducing stockouts by an estimated 12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Security of Medical Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecent policy pushes aim to secure essential medicine supplies after COVID-19 and 2022–24 supply shocks; regulators now expect wholesalers to hold 90+ days of critical drug inventory, with Japan's Ministry of Health citing a 35% rise in emergency stockpile mandates in 2024. The government incentivizes sourcing diversification and local production, offering subsidies covering up to 30% of warehousing upgrades. Medipal’s investments include ¥12.4 billion in disaster-resistant distribution centers and expanded cold-chain capacity to support national resilience and meet mandated stockpile targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for Specialty and Orphan Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical initiatives offering tax credits and fast-track approvals for orphan drugs have increased global drug sales to billion in which medipal leverages by expanding ultra-cold chain capacity biologics regenerative therapies.\u003e\n\u003cpthis alignment with government priorities enables medipal to target high-growth niches improving market share in specialty distribution where margins exceed traditional pharma by percentage points.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal orphan drug market: $263B (2024)\u003c\/li\u003e\n\u003cli\u003eMedipal investment: expanded ultra-cold logistics for biologics\u003c\/li\u003e\n\u003cli\u003eHigher margins: specialty vs traditional +6–10 pp\u003c\/li\u003e\n\u003cli\u003eCompetitive edge in high-growth niche markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Security and Supply Chain Resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJapanese authorities, citing supply-chain risks after COVID-19 and 2022–24 geopolitical tensions, push policies boosting domestic API stockpiles and resilient logistics; METI’s 2024 guidance targets a 30% domestic sourcing increase for strategic medical items by 2030.\u003c\/p\u003e\n\u003cp\u003eMedipal, with roughly 60% of APIs imported in 2025 for key therapeutic lines, must track regulatory shifts, adjust procurement, and invest in local storage\/logistics to keep import-dependent segments compliant and operational.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMETI 2024 goal: +30% domestic sourcing for strategic medical items by 2030\u003c\/li\u003e\n\u003cli\u003eMedipal import exposure ~60% of APIs in 2025\u003c\/li\u003e\n\u003cli\u003eRequired actions: monitor regulations, expand domestic storage, strengthen logistics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedipal pivots to specialty and logistics as drug-price cuts, sourcing rules bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment drug-price cuts (−1.6% in 2024; \u0026gt;10% since 2015) and supply-security mandates (90+ day stockpiles; METI +30% domestic sourcing by 2030) pressure Medipal’s margins and sourcing; company invested ¥12.4bn in resilient logistics, expanded ultra-cold capacity for orphan drugs (global sales $263B in 2024) and shifted mix to higher-margin specialty lines (+6–10 pp).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 price revision\u003c\/td\u003e\n\u003ctd\u003e−1.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative price cuts since 2015\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan drug market (2024)\u003c\/td\u003e\n\u003ctd\u003e$263B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedipal logistics capex\u003c\/td\u003e\n\u003ctd\u003e¥12.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs imported (2025)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Medipal Holdings across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trends to identify threats and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a distilled PESTLE view of Medipal Holdings for quick reference in meetings or presentations, visually separated by category and written in clear language to support fast risk assessment and strategic alignment across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Logistics and Energy Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation in Japan pushed fuel and electricity costs up about 7.5% year-on-year in 2024, increasing transportation labor and energy expenses for Medipal’s distribution network.\u003c\/p\u003e\n\u003cp\u003eWith many pharmaceutical products sold under fixed-margin contracts, these higher overheads compress gross margins and pressured operating profit in FY2024.\u003c\/p\u003e\n\u003cp\u003eMedipal is consolidating shipments across its Area Logistics Centers and investing in LED, solar and heat-pump systems, targeting a 10–15% reduction in energy costs per center over 2024–2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Currency Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFluctuations in the Japanese yen materially affect Medipal Holdings: a 10% yen weakening raised imported raw material and cosmetics procurement costs by an estimated ¥12–18bn in FY2024, squeezing margins as price-sensitive consumers limit pass-through. A weaker yen also inflated finished-goods COGS for the cosmetics division, reducing gross margin by ~1.2 percentage points in 2024. Medipal mitigates FX risk via hedging—forward contracts covering ~40% of anticipated imports—and strategic sourcing shifts to ASEAN suppliers, lowering FX exposure by roughly 15% since 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Drug Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe global generic drug market reached about USD 430 billion in 2024 with Japan’s generics penetration rising to ~85% of prescriptions by volume, pressuring wholesalers like Medipal with slimmer margins on generic SKUs.\u003c\/p\u003e\n\u003cp\u003eAs brand-name volumes plateau, Medipal must drive higher distribution volumes and efficiency—its FY2024 gross margin fell slightly to 8.9%, highlighting the need for scale.\u003c\/p\u003e\n\u003cp\u003eTo offset margin compression the company is expanding value-added services—logistics, IT integration, and inventory management—which contributed an estimated 6% of revenue in FY2024 and aims to boost per-pharmacy revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending in the Retail Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsumer spending in Japan dipped 0.5% YoY in 2024 Q3, tightening demand for premium cosmetics and daily necessities and making the wholesale cosmetics segment highly sensitive to disposable income and sentiment shifts.\u003c\/p\u003e\n\u003cp\u003eEconomic stagnation and moves toward value-oriented buying reduced premium beauty sales by an estimated 6–8% in 2024 amid rising living costs.\u003c\/p\u003e\n\u003cp\u003eMedipal uses transaction and POS analytics to optimize retailer assortments, improving SKU profitability and reducing stockouts by up to 12% in pilot programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Q3 household spending down 0.5% YoY\u003c\/li\u003e\n\u003cli\u003ePremium beauty sales -6–8% in 2024\u003c\/li\u003e\n\u003cli\u003eMedipal analytics cut stockouts ~12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment in Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs the Bank of Japan exited negative rates in 2023 and raised the policy rate to around 0.1–0.3% by 2025, borrowing costs for capital projects in Japan have risen, pressuring Medipal’s financing for distribution automation and warehouse builds.\u003c\/p\u003e\n\u003cp\u003eMedipal’s ¥200–300bn capex program and reliance on bank loans and bonds make prudent capital structure management and cash-flow forecasting essential to sustain logistics investment without eroding margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBOJ policy rate ~0.1–0.3% (2025)\u003c\/li\u003e\n\u003cli\u003eMedipal capex ~¥200–300bn\u003c\/li\u003e\n\u003cli\u003eHigher rates raise debt service and affect ROI on automation\u003c\/li\u003e\n\u003cli\u003eNeed for tighter cash-flow and diversified funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, weak yen squeeze Medipal margins as ¥200–300bn capex looms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation raised energy\/transport costs ~7.5% YoY in 2024, compressing FY2024 gross margin to 8.9%; weaker yen added ¥12–18bn to import costs; generics market ~USD 430bn with 85% Japan penetration; BOJ rate ~0.1–0.3% (2025) increasing capex funding pressure on Medipal’s ¥200–300bn program; value-added services = ~6% revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy cost rise\u003c\/td\u003e\n\u003ctd\u003e+7.5% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e8.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImport FX impact\u003c\/td\u003e\n\u003ctd\u003e¥12–18bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics market\u003c\/td\u003e\n\u003ctd\u003eUSD 430bn (85% Japan)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBOJ rate\u003c\/td\u003e\n\u003ctd\u003e0.1–0.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e¥200–300bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMedipal Holdings PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Medipal Holdings PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751269806457,"sku":"medipal-hd-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medipal-hd-pestle-analysis.png?v=1772229541","url":"https:\/\/matrixbcg.com\/products\/medipal-hd-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}